- Open Access
Absorbable hydrogel spacer use in men undergoing prostate cancer radiotherapy: 12 month toxicity and proctoscopy results of a prospective multicenter phase II trial
© Uhl et al.; licensee BioMed Central Ltd. 2014
- Received: 19 October 2013
- Accepted: 15 April 2014
- Published: 24 April 2014
Radiation therapy is one of the recommended treatment options for localized prostate cancer. In randomized trials, dose escalation was correlated with better biochemical control but also with higher rectal toxicity. A prospective multicenter phase II study was carried out to evaluate the safety, clinical and dosimetric effects of the hydrogel prostate-rectum spacer. Here we present the 12 months toxicity results of this trial.
Fifty two patients with localized prostate cancer received a transperineal PEG hydrogel injection between the prostate and rectum, and then received IMRT to a dose of 78 Gy. Gastrointestinal and genitourinary toxicity were recorded during treatment and at 3, 6 and 12 months following irradiation by using the RTOG/EORTC criteria. Additionally, proctoscopy was performed 12 months after treatment and the results were scored using the Vienna Rectoscopy Scale (VRS).
Of the patients treated 39.6% and 12.5% experienced acute Grade 1 and Grade 2 GI toxicity, respectively. There was no Grade 3 or Grade 4 acute GI toxicity experienced in the study. Only 4.3% showed late Grade 1 GI toxicity, and there was no late Grade 2 or greater GI toxicity experienced in the study. A total of 41.7%, 35.4% and 2.1% of the men experienced acute Grade 1, Grade 2 and Grade 3 GU toxicity, respectively. There was no Grade 4 acute GU toxicity experienced in the study. Late Grade 1 and Grade 2 GU toxicity was experienced in 17.0% and 2.1% of the patients, respectively. There was no late Grade 3 or greater GU toxicity experienced in the study. Seventy one percent of the patients had a VRS score of 0, and one patient (2%) had Grade 3 teleangiectasia. There was no evidence of ulceration, stricture or necrosis at 12 months.
The use of PEG spacer gel is a safe and effective method to spare the rectum from higher dose and toxicity.
- Prostate cancer
- Rectal toxicity
Prostate cancer is the most common cancer in older men in the USA and Europe. The predicted 2013 prostate cancer death rate in Europe is 10.5/100.000 men. Despite treatment advances, prostate cancer still ranks third in cancer death, after lung and colon carcinoma. Furthermore, the incidence of new prostate cancer cases in 2010 was the highest of cancers among men in developed countries across the globe. Radiation therapy or prostatectomy are often the recommended treatment options for localized prostate cancer[3, 4]. In patients undergoing prostate radiotherapy biochemical control is improved with dose escalation. However, dose escalation can also increase rectal toxicity due to the prostate - rectum proximity. Although highly conformal techniques like imaged guided radiation therapy (IMRT) are able to improve dose sparing of the rectum wall, the dose to the anterior rectal wall remains high[6–8]. The dose escalation study of Kuban, et al., was able to demonstrate a direct relationship between the volume of treated rectum and rectal toxicity. The Heemsbergen et al. publication on 553 evaluable patients from the Dutch dose escalation trial demonstrated a correlation between the acute toxicity and frequency of late rectal toxicity. Several methods have been developed to create space between the prostate and rectum to allow for prostate dose escalation while reducing rectal wall irradiation[10–12]. One of these methods is a polyethylene glycol (PEG) hydrogel that is injected between the rectum and the prostate before treatment planning and remains stable over the treatment period. A prospective multicenter phase II study was carried out to evaluate the safety, clinical, and dosimetric effects of the hydrogel prostate-rectum spacer. Fifty-two men with localized prostate cancer were included in this trial[13, 14]. In February 2013 Uhl et al. published the initial clinical outcomes with acute toxicity results of the first 48 patients and late toxicity of the first 27 patients. Six patients (12%) experienced acute Grade 2 GI toxicity (no Grade 3 or 4 toxicity), while Grade 2 and Grade 3 GU toxicity was experienced in 17 (35%) and 1 (2%) of the patients, respectively. One year after the end of therapy no Grade 2 or higher GU/GI toxicity occurred. This publication presents the results from all patients following study completion, 12 months following completion of EBRT and includes results of planned proctoscopic evaluation.
As previously described 52 men with pathologically confirmed stage T1 or T2 prostate cancer were evaluated in this prospective, non-randomized, multi-center, single arm, open-label trial. The study included otherwise healthy patients with prostates < 80 cc, PSA ≤ 20 ng/mL, Gleason Score ≤ 6 or Gleason Score 7 with a grade 3 predominant pattern. Excluded were patients with metastatic disease, planned pelvic lymph node radiotherapy, prior prostate surgery, uncontrolled diabetes, chronic systemic corticosteroid therapy, prior prostate or pelvis radiation therapy, active bleeding disorder, historical or active inflammatory bowel disease, or a history of rectal or gastrointestinal surgery. Androgen deprivation therapy was not an exclusion criteria. Following local Ethics Committee approvals patients were enrolled at the University of Heidelberg (n = 21), University of Aachen (n = 20), NKI-AVL Nederlands Kanker Instituut Amsterdam (n = 7) and University of Geneva (n = 4).
Acute and late GI/GU toxicity (Maximum score)
GI toxicity scores (n %)
GU toxicity scores (n %)
Grade 1 or worse
Grade 2 or worse
The use of PEG spacer gel is a safe and effective method to spare the rectum from higher dose and toxicity. Due to fewer late side effects on the rectum, along with the potential of enabling hypofractionation and dose escalation, the hydrogel spacer may lead to lower costs for the healthcare system.
- Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E: European cancer mortality predictions for the year 2013. Ann Oncol 2013, 24: 792-800. 10.1093/annonc/mdt010View ArticlePubMedGoogle Scholar
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61: 69-90. 10.3322/caac.20107View ArticlePubMedGoogle Scholar
- Bucci MK, Bevan A, Roach M 3rd: Advances in radiation therapy: conventional to 3D, to IMRT, to 4D, and beyond. CA Cancer J Clin 2005, 55: 117-134. 10.3322/canjclin.55.2.117View ArticlePubMedGoogle Scholar
- Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, European Association of Urology: EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011, 59: 61-71. 10.1016/j.eururo.2010.10.039View ArticlePubMedGoogle Scholar
- Viani GA, Stefano EJ, Afonso SL: Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized controlled trials. Int J Radiat Oncol Biol Phys 2009, 74: 1405-1418. 10.1016/j.ijrobp.2008.10.091View ArticlePubMedGoogle Scholar
- Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK, Pollack A: Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70: 67-74. 10.1016/j.ijrobp.2007.06.054View ArticlePubMedGoogle Scholar
- Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA: High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001, 166: 876-881. 10.1016/S0022-5347(05)65855-7View ArticlePubMedGoogle Scholar
- Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, Bush DA, Lunt M, Spiegel DY, Skowronski R, Jabola BR, Rossi CJ: Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95–09. J Clin Oncol 2010, 28: 1106-1111. 10.1200/JCO.2009.25.8475PubMed CentralView ArticlePubMedGoogle Scholar
- Heemsbergen WD, Peeters ST, Koper PC, Hoogeman MS, Lebesque JV: Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. Int J Radiat Oncol Biol Phys 2006, 66: 3-10. 10.1016/j.ijrobp.2006.03.055View ArticlePubMedGoogle Scholar
- Noyes WR, Hosford CC, Schultz SE: Human collagen injections to reduce rectal dose during radiotherapy. Int J Radiat Oncol Biol Phys 2012, 82: 1918-1922. 10.1016/j.ijrobp.2011.02.034View ArticlePubMedGoogle Scholar
- Prada PJ, Fernandez J, Martinez AA, de la Rúa A, Gonzalez JM, Fernandez JM, Juan G: Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients. Int J Radiat Oncol Biol Phys 2007, 69: 95-102. 10.1016/j.ijrobp.2007.02.034View ArticlePubMedGoogle Scholar
- Wilder RB, Barme GA, Gilbert RF, Holevas RE, Kobashi LI, Reed RR, Solomon RS, Walter NL, Chittenden L, Mesa AV, Agustin J, Lizarde J, Macedo J, Ravera J, Tokita KM: Cross-linked hyaluronan gel reduces the acute rectal toxicity of radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010, 77: 824-830. 10.1016/j.ijrobp.2009.05.069View ArticlePubMedGoogle Scholar
- Song DY, Herfarth KK, Uhl M, Eble MJ, Pinkawa M, van Triest B, Kalisvaart R, Weber DC, Miralbell R, Deweese TL, Ford EC: A multi-institutional clinical trial of rectal dose reduction via injected polyethylene-glycol hydrogel during intensity modulated radiation therapy for prostate cancer: analysis of dosimetric outcomes. Int J Radiat Oncol Biol Phys 2013, 87: 81-87. 10.1016/j.ijrobp.2012.12.019PubMed CentralView ArticlePubMedGoogle Scholar
- Uhl M, van Triest B, Eble MJ, Weber DC, Herfarth K, De Weese TL: Low rectal toxicity after dose escalated IMRT treatment of prostate cancer using an absorbable hydrogel for increasing and maintaining space between the rectum and prostate: results of a multi-institutional phase II trial. Radiother Oncol 2013, 106: 215-219. 10.1016/j.radonc.2012.11.009View ArticlePubMedGoogle Scholar
- Hatiboglu G, Pinkawa M, Vallee JP, Hadaschik B, Hohenfellner M: Application technique: placement of a prostate-rectum spacer in men undergoing prostate radiation therapy. BJU Int 2012, 110: E647-E652. 10.1111/j.1464-410X.2012.11373.xView ArticlePubMedGoogle Scholar
- Cox JD, Stetz J, Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995,31(5):1341-1346. 10.1016/0360-3016(95)00060-CView ArticlePubMedGoogle Scholar
- Wachter S, Gerstner N, Goldner G, Potzi R, Wambersie A, Potter R: Endoscopic scoring of late rectal mucosal damage after conformal radiotherapy for prostatic carcinoma. Radiother Oncol 2000, 54: 11-19. 10.1016/S0167-8140(99)00173-5View ArticlePubMedGoogle Scholar
- Lips IM, Dehnad H, van Gils CH, Boeken Kruger AE, van der Heide UA, van Vulpen M: High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients. Radiat Oncol 2008, 3: 15. 10.1186/1748-717X-3-15PubMed CentralView ArticlePubMedGoogle Scholar
- Vora SA, Wong WW, Schild SE, Ezzell GA, Halyard MY: Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2007, 68: 1053-1058. 10.1016/j.ijrobp.2007.01.043View ArticlePubMedGoogle Scholar
- Ippolito E, Massaccesi M, Digesu C, Deodato F, Macchia G, Pirozzi GA, Cilla S, Cuscunà D, Di Lallo A, Mattiucci GC, Mantini G, Pacelli F, Valentini V, Cellini N, Ingrosso M, Morganti AG: Early proctoscopy is a surrogate endpoint of late rectal toxicity in prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2012, 83: e191-e195. 10.1016/j.ijrobp.2011.06.1960View ArticlePubMedGoogle Scholar
- Goldner G, Tomicek B, Becker G, Geinitz H, Wachter S, Zimmermann F, Wachter-Gerstner N, Reibenwein J, Glocker S, Bamberg M, Feldmann H, Pötzi R, Molls M, Pötter R: Proctitis after external-beam radiotherapy for prostate cancer classified by Vienna rectoscopy score and correlated with EORTC/RTOG score for late rectal toxicity: results of a prospective multicenter study of 166 patients. Int J Radiat Oncol Biol Phys 2007, 67: 78-83. 10.1016/j.ijrobp.2006.08.055View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.